Tips for Patients Using Pumps

Experts agree with the following steps*:

* Choose a part of the body

* Always use a new site



- * Divide into 4 areas
- * Use one area every 7-14 days depending on your pump set * Follow your health care professional's recommendations for site rotation


Use for diabetes-related injection-induced scarring

Scarring from on-going use of wearables can significantly impact glycemic control

- ▶ **GREATER** glycemic variability up to 7 times higher*
- ▶ INCREASED use of insulin up to 35% more⁺

* Avoid using a single site more than once every 4 weeks

▶ HIGHER A1c level - up to 0.55 higher*



STEP 1: Apply

Holding embrace[®] on its outer edges, use the Peel Tabs to peel off the clear protective liner that covers the adhesive patch.

DO NOT touch the adhesive patch with your fingers.



STEP 2: Release

Use one hand to hold

skin.



Gently bow the Applicator with both hands to remove any creases and pockets.



Position embrace® over the injection/scarred area so that the Applicator is parallel to the length of the area and faces away from your skin.

PRESS AND HOLD

embrace® against the skin for 60 seconds. Make sure to press down firmly on the edges and corners.




Holding embrace[®] against your skin with one hand, use your other hand to pull one Release Tab to the side and along the edge of the Applicator.

Repeat this step with the other Release Tab. The Applicator will completely detach, leaving the patch adhered to the skin.

Smooth out any uneven areas, flatten any air pockets, and secure any raised corners or edges.





Example for 3 Day pump infusion set site rotation with embrace medium



Example for 7 Day pump infusion set site rotation with embrace small



* Frid, A. H., Hirsch, L. J., Menchior, A. R., Morel, D. R. & Strauss, K.W. Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional. Mayo Clin Proc 91, 1224-1230, doi:10.1016/j.mayocp.2016.06.012 (2016).
† Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi: 10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22. PMID: 23886784.
* Frid AH, Kreugel G, Grassi G, et.al. New insulin delivery recommendations. Mayo Clic. Proc. 2016-91(9): 1231-1255



We're here to support your use of embrace® to make sure you experience the best possible results. Contact us for questions or additional information.

EMBRACE is a registered trademark of Neodyne Biosciences, Inc. All other trademarks are the property of their respective owners. © Neodyne Biosciences, Inc. All Rights Reserved.

1-855-722-7879 Mon-Fri 8AM-4:30PM EST support@neodynebio.com www.EmbraceDiabetesCare.com